Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 7/20 | 0.59 |
| ▸ | MMP7 | P09237 | 7/20 | 0.59 |
| ▸ | MMP12 | P39900 | 7/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054238 | 1.00 | MMP3 (0.59) | MMP3MMP7MMP12MMP2ADAM17 | |
| SCHEMBL4050516 | 0.83 | AR (0.46) | MMP3MMP7MMP12MMP2ADAM17 | |
| SCHEMBL4050512 | 0.83 | AR (0.46) | MMP3MMP7MMP12MMP2ADAM17 | |
| SCHEMBL4052563 | 0.81 | ADAM17 (0.59) | MMP3MMP7MMP2ADAM17 | |
| SCHEMBL4052485 | 0.81 | ADAM17 (0.59) | MMP3MMP7MMP2ADAM17 | |
| SCHEMBL4052481 | 0.81 | ADAM17 (0.59) | MMP3MMP7MMP2ADAM17 | |
| SCHEMBL4049750 | 0.79 | ADAM17 (0.60) | MMP3MMP7ADAM17 | |
| SCHEMBL4049753 | 0.79 | ADAM17 (0.60) | MMP3MMP7ADAM17 | |
| SCHEMBL4056371 | 0.79 | ADAM17 (0.45) | MMP3MMP7MMP12MMP2ADAM17 | |
| SCHEMBL4060509 | 0.79 | ADAM17 (0.37) | MMP3MMP7MMP12MMP2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | claimed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | claimed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | claimed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | claimed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | MMP3 7/4885MMP7 18/4885MMP12 26/4885 |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM9 | MMP3 12/4885MMP7 18/4885MMP12 23/4885 |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAMTS1, ADAM8 | MMP3 7/4885MMP7 18/4885MMP12 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.